Vaccine sales reflects the challenges we've seen from external pressures in the U.S. and China for Arexvy and Shingrix. Going forward, we expect these to continue in 2025, but equally remain ...

Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million ...

This number is significantly low when compared to the sales of currently marketed RSV vaccines Arexvy and Abrysvo, marketed by pharma giants GSK and Pfizer, respectively. The softer sales ...

Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million to ...

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.

A key therapeutic point is to avoid re-traumatising investors, as GSK did fairly recently with respiratory syncytial virus jab Arexvy. The company had promoted it as proof of how it is now able to ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

with a modest 1% increase in Shingrix sales but a steep 51% drop in Arexvy sales. Despite this, general medicines sales grew by 6%. GSK's operating profit was impacted by approximately £403 ...

IPC Indice de Precios Y Cotizaciones 52,926.31 108.56 0.21% ...